China
Africa
Explore chapters and articles related to this topic
Ceftolozane and Ceftolozane–Tazobactam
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Ceftolozane has a similar spectrum of activity to ceftazidime but with greater efficacy against Pseudomonas aeruginosa. It has limited activity against Gram-positive organisms and broader activity against Gram-negative organisms; however, when tazobactam is added to ceftolozane, the efficacy against Gram-negative organisms—particularly, beta-lactamase-producing organisms, including ESBL producers—improves.
The safety of ceftolozane/tazobactam for the treatment of complicated urinary tract infections
Published in Expert Opinion on Drug Safety, 2023
Matteo Bassetti, Antonio Vena, Daniele Roberto Giacobbe
Ceftolozane has a pharmacokinetics/pharmacodynamics (PK/PD) which is similar to that of other cephalosporins. The PK of ceftolozane is dose-linear, and its mean plasma half-life and volume of distribution (Vd) at steady state are 2–3 hours and 21–18 Liters, respectively [12]. The protein binding of ceftolozane is 20% and its rate of renal excretion is > 90% [12,13]. The PK of tazobactam is linear and not affected when co-administered with ceftolozane, differently from when tazobactam is administered with piperacillin [14,15]. C/T does not show high cerebrospinal fluid penetration [16]. C/T has no significant drug-drug interactions since it is not a substrate or a modulator of cytochrome P450 enzymes [17,18]. The plasma concentrations of tazobactam can be increased by co-administration with inhibitors of organic anion transporters 1 (OAT1) and 3 (OAT3), such as probenecid [17]. Regarding PD, the bactericidal activity of ceftolozane is time-dependent, and the percentage of time that the free drug concentration is above the minimum inhibitory concentration (MIC) across doses is the best predictor of drug activity [12].
Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia
Published in Expert Review of Anti-infective Therapy, 2020
Ignacio Martin-Loeches, Alessandra Bisanti, Emili Diaz, Alejandro Rodriguez
Finally, a phase 1, open-label, multi-center study (18 USA centers) was performed to evaluate the PK, safety, and tolerability of single IV doses of ceftolozane in children from birth (7 days postnatal) to <18 years with proven/suspected Gram-negative infections, or if the children were receiving perioperative prophylaxis [32]. Thirty-seven patients were enrolled in six groups according to age, and given ceftolozane (safety population), 34 patients comprised the PK population. Overall, ceftolozane PK was comparable among children older than 3 months, following administration of single IV doses of ceftolozane (between 20/10 and 30/15 mg/kg according to age). The CL of ceftolozane and tazobactam appeared to be lower and the volume of distribution was slightly higher, in young infants and neonates (7 days postnatal) in comparison to older children. This lower CL observed in young infants and neonates was most likely due to their immature renal function. Therefore, the ceftolozane/tazobactam dose should be adjusted accordingly in this age group (20/10 mg/kg). Although the number of participants was lower in each subgroup, ceftolozane/tazobactam was typically tolerated well; no safety concerns were identified.
Pharmacotherapeutic advances for recurrent urinary tract infections in women
Published in Expert Opinion on Pharmacotherapy, 2020
Mohamad Moussa, Mohamed Abou Chakra, Athanasios Dellis, Yasmin Moussa, Athanasios Papatsoris
Ceftolozane–tazobactam (C-T) is a new combination of a cephalosporin with a β-lactamase inhibitor that shows excellent in vitro activity against a broad spectrum of Enterobacteriaceae and Pseudomonas aeruginosa, including ESBL strains. C-T primarily shows in vitro activity against many aerobic Gram-negative bacilli, including most ESBL-producing E. coli (particularly TEM- and CTX-M-type ESBLs) [112]. The dose of C-T is 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) intravenously every 8 hours given as a 1-hour infusion. Ceftolozane has low plasma protein binding (20%) and is predominantly excreted unchanged in the urine (≥ 92%). Dosage adjustments are required for moderate-to-severe renal impairment and in patients receiving hemodialysis [113].